Skip to main content

Advertisement

SpringerLink
Log in

Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol

  • Review
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Severe vitamin D deficiency was identified only in the first decades of the last century as the most common aetiology of rickets in children and osteomalacia in adults. It was later shown that vitamin D is not, as had been supposed, the biologically active principle for healing bone disease but must be hydroxylated in the liver and then finally in the kidney to become 1α,25-dihydroxy-cholecalciferol, a biologically highly active renal hormone. This study reviews the various principles, mechanisms, and approaches to the treatment of different forms of osteoporosis using vitamin D, alfacalcidol, and calcitriol therapy regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Mellanby E (1919) An experimental investigation of rickets. Lancet 1:407–411

    Google Scholar 

  2. Huldschinsky K (1919) Heilung von Rachitis durch künstliche Höhensonne. Dtsch Med Wschr 45:712–717

    Google Scholar 

  3. McCollum EV, Simmonds N, Becker JE, Shipley PG (1922) Studies on experimental rickets. XXI: an experimental demonstration of the existence of a vitamin which promotes calcium deposition. J Biol Chem 53:293–296

    CAS  Google Scholar 

  4. Windaus A, Linsert O (1928) Vitamin D. Justus Liebigs Ann Chem 465:148–155

    CAS  Google Scholar 

  5. De Luca H (1978) Vitamin D metabolism and function. Arch Intern Med 138:836–847

    PubMed  Google Scholar 

  6. De Luca H (1988) The vitamin D story: a collaborative effort of basic science and clinical medicine. Fed Proc Am Soc Exp Biol 2:1083–1086

    Google Scholar 

  7. Slatoplosky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ (1984) Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136–2143

    PubMed  Google Scholar 

  8. Hamdy NAT, Kanis JA, Beneton MNC, Brown CB, Juttmann JR, Jordans JGM, Josse S, Meyrier A, Llins R, Fairey IT (1995) Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Br Med J 310:358–363

    CAS  Google Scholar 

  9. Schömig M, Lamichhane B, Ritz E (2000) Renal bone disease. In: Hosking D, Ringe JD (eds) Treatment of metabolic bone disease. Dunitz, London

  10. Ogata E (1990) Hypoparathyroidism: practice and theoretical background for 1α-OH-D treatment. Bone Miner 9:229–232

    Article  CAS  PubMed  Google Scholar 

  11. Cundy T (2000) Hypoparathyroidism. In: Hosking D, Ringe JD (eds) Treatment of metabolic bone disease. Dunitz, London

  12. Pettifor JM (1990) Recent advances in pediatric metabolic bone disease: the consequences of altered phosphate homeostasis in renal insufficiency and hypophosphatemic vitamin D resistant rickets. Bone Miner 9:199–214

    Article  CAS  PubMed  Google Scholar 

  13. Davies M (2000) Treatment of osteomalacia. In: Hosking D, Ringe JD (eds)Treatment of metabolic bone disease. Dunitz, London

  14. McKenna MJ (1992) Differences in vitamin D status between countries in young adults and the elderly. Am J Med 93:69–77

    Article  CAS  PubMed  Google Scholar 

  15. Krexner E, Resch H, Pietschmann P, Bernecker P, Woloscuk W, Vukovich T, Geyer G, Willvonseder R (1996) Vitamin D status in residents of a long-term-care geriatric hospital in Vienna. Osteologie 5:13–18

    Google Scholar 

  16. Chapuy MC, Durr F, Chapuy P (1983) Age-related changes in parathyroid hormone and 25-hydroxycholecalciferol levels. J Gerontol 38:19–22

    CAS  PubMed  Google Scholar 

  17. Chapuy MC, Chapuy C, Meunier PJ (1987) Calcium and vitamin D supplements: effects on calcium metabolism in elderly people. Am J Clin Nutr 46:324–328

    CAS  PubMed  Google Scholar 

  18. Chapuy MC, Arlot ME, DuBoef F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637–1642

    CAS  PubMed  Google Scholar 

  19. Chapuy MC, Schott AM, Garnero P, Hans D, Delmas P, Meunier PJ (1996) Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. J Clin Endocrinol Metab 81:1129–1133

    Article  CAS  PubMed  Google Scholar 

  20. Heinkinheimo R, Sievänen R, Jäntti P, Mäki-Jokela PL, Rajala S, Vuori I (1996) Vitamin D treatment and bone mineral density in the aged. Maturitas 23 [Suppl]:S77–S80

  21. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 337:670–676

    Article  CAS  PubMed  Google Scholar 

  22. Amin S, LaValley MP, Simms RW, Felson DT (1999) The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 42:1740–1751

    Article  CAS  PubMed  Google Scholar 

  23. Normann AW (2001) Vitamin D. In: Bowman B, Russell R (eds) Present knowledge in nutrition. International Life Sciences Institute, Washington DC

  24. Haussler MR (1986) Vitamin D receptors: nature and function. Annu Rev Nutr 6:527–562

    Article  CAS  PubMed  Google Scholar 

  25. Webb AR, Kline L, Holick MF (1988) Influence of season and latitude on cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in the skin. J Clin Endocrinol Metab 67:373–378

    CAS  PubMed  Google Scholar 

  26. Sherman SS, Hollis BW, Tobin JD (1990) Vitamin D status and related parameters in a healthy population: the effects of age, sex, and season. J Clin Endocrinol Metab 71:405–413

    CAS  PubMed  Google Scholar 

  27. Lau KHW, Baylink DJ (1999) Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D hormone) therapy. Calcif Tissue Int 65:295–306

    Article  CAS  PubMed  Google Scholar 

  28. Papopoulos SG, Fraher LJ, Sandler LM, Clemens TL, Lewin IG, O’Riordan JLH (1979) 1,25-dihydroxycholecalciferol in the pathogenesis of hypercalcemia of sarcoidosis. Lancet 1:627–631

    Article  PubMed  Google Scholar 

  29. Avioli LV (1999) Vitamin D and the D hormones, alfacalcidol and calcitriol, as therapeutic agents for osteoporotic populations. Calcif Tissue Int 65:292–294

    Article  CAS  PubMed  Google Scholar 

  30. Ichikawa F, Sato K, Nanjo M, Nishi Y, Shinki T, Takahahi N, Suda T (1995) Mouse primary osteoblasts express vitamin D 25-hydroxylase mRNA and convert 1α,25-dihydroxyvitamin D3. Bone 16:129–135

    Article  CAS  PubMed  Google Scholar 

  31. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama T, Matsumoto T, Ogata E (2000) Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 15:770–779

    CAS  PubMed  Google Scholar 

  32. Dambacher MA, Schacht E (1996) Osteoporosis and active vitamin D metabolites. The shape of things to come. EULAR, Basel

  33. Seino I, Tanaka H, Yamaoka K, Yabucchi H (1987) Circulating 1α,25-dihydroxyvitamin D3 levels after a single dose of 1α,25-dihydroxyvitamin D3 or 1α-hydroxyvitamin D3 in normal men. Bone Miner 2:479–485

    CAS  PubMed  Google Scholar 

  34. Hosking DJ, Campbell GA, Kemm JR, Cotton RE, Boyd RV (1984) Safety of treatment for subclinical osteomalacia in the elderly. Br Med J 289:785–787

    CAS  Google Scholar 

  35. Lips P, Graafsmans WC, Ooms ME, Bezemer PD, Bouter LM (1996) Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med 124:400–406

    CAS  PubMed  Google Scholar 

  36. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323

    Article  CAS  PubMed  Google Scholar 

  37. Papadimitropoulos E, Wells G, Shea B (2002) Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocrine Reviews 23:560–569

    Article  CAS  PubMed  Google Scholar 

  38. Scharla SH, Schacht E, Bawey S, Kamilli I, Holle D, Lempert UG (2003) Pleiotropic effects of 1-alfa-hydroxyvitamin D (alfacalcidol) in patients with rheumatoid arthritis. Arthritis Rheum 23:268–274

    Google Scholar 

  39. Lau KHW, Baylink DJ (2001) Treatment of 1,25(OH)2D3 (D-hormone) deficiency/resistance with D hormone and analogs. Osteologie 10:28–39

    Google Scholar 

  40. Bischoff HA, Stähelin HB, Urscheler N (1999) Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 80:54–58

    Article  CAS  PubMed  Google Scholar 

  41. Mowe M, Haug E, Bohmer T (1999) Low serum calcidiol concentration in older adults with reduced muscular function. J Am Geriatr Soc 47:220–226

    CAS  PubMed  Google Scholar 

  42. Glerup H, Mikkelsen H, Poulsen L, Hass ER, Overbeck S, Andersen H, Charles P, Eriksen EF (2000) Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int 66:419–424

    Article  CAS  PubMed  Google Scholar 

  43. Simpson RU, Thomas GA, Arnold AJ (1985) Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem 260:8882–8891

    CAS  PubMed  Google Scholar 

  44. Bischoff HA, Borchers M, Gudat F (2001) In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 33:19–24

    Article  CAS  PubMed  Google Scholar 

  45. Boland R (1986) Role of vitamin D in skeletal muscle function. Endocrine Reviews 7:434–447

    CAS  PubMed  Google Scholar 

  46. Sorenson OH, Lund B, Saltin B (1979) Myopathy in bone loss of aging: improvement by treatment with 1-alphahydroxycholecalciferol and calcium. Clin Sci (Colch) 56:157–161

    Google Scholar 

  47. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C (2000) Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 15:1113–1118

    CAS  PubMed  Google Scholar 

  48. Bischoff HA, Stähelin HB, Dick W (2003) Effects of vitamin D and calcium supplementation on falls: a randomised controlled trial. J Bone Miner Res 18:343–351

    CAS  PubMed  Google Scholar 

  49. Müller K, Diamant M, Bendtzen K (1991) Inhibition of interleukin-6 by 1,25-dihydroxyvitamin D3. Immunol Lett 28:115–120

    Article  PubMed  Google Scholar 

  50. DeLuca HF, Cantorna MT (2001) Vitamin D. Its role and uses in immunology. FASEB J 15:2579–2585

    Article  CAS  PubMed  Google Scholar 

  51. Mathieu C, Adorini L (2002) The coming age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med 8:174–179

    Article  CAS  PubMed  Google Scholar 

  52. Ringe JD (1997) Active vitamin D metabolites in glucocorticoid-induced osteoporosis. Calcif Tissue Int 60:124–127

    Article  CAS  PubMed  Google Scholar 

  53. Ringe JD, Cöster A, Meng T, Schacht E, Umbach R (1999) Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 63:337–340

    Article  Google Scholar 

  54. Ringe JD, Faber H (2000) Calcium and vitamin D in the prevention and treatment of glucocorticoid-induced osteoporosis. Clin Exp Rheumatol 18 [Suppl 21]:S44–S48

  55. Hayashi Y, Fujita T, Inoue T (1992) Decrease of vertebral fracture in osteoporosis by administration of 1α-hydroxy-vitamin D3. JBMM 10:184–188

    Google Scholar 

  56. Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S (1994) Effects of 1α-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370–376

    CAS  PubMed  Google Scholar 

  57. Shiraki M, Kushida K, Yamazaki K, Nagai T, Inoue T, Orimo H (1996) Effects of 2 years’ treatment of osteoporosis with 1α-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocr J 43:211–220

    CAS  PubMed  Google Scholar 

  58. Sato Y, Maruoka H, Oizumi K (1997) Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1α-hydroxyvitamin D3 and calcium supplementation. Stroke 28:736–739

    CAS  PubMed  Google Scholar 

  59. Dechant KL, Goa KL (1994) Calcitriol. A review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis. Drugs Aging 5:300–317

    CAS  PubMed  Google Scholar 

  60. Menczel J, Foldes J, Steinberg R, Leichter I, Shalita B, Bdolah-Abram T et al (1994) Alfacalcidol (alpha D3)and calcium in osteoporosis. Clin Orthop 300:241–247

    PubMed  Google Scholar 

  61. Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J et al (2000) Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 59 [Suppl 1]:48–52

    Google Scholar 

  62. Gallagher JC, Riggs BL, Recker RR, Goldgar D (1989) The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 191:287–292

    CAS  PubMed  Google Scholar 

  63. Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Intern Med 113:649–655

    CAS  PubMed  Google Scholar 

  64. Tilyard MW, Spears GFS, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol and calcium. N Engl J Med 326:357–362

    CAS  PubMed  Google Scholar 

  65. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N et al (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747–1752

    Article  CAS  PubMed  Google Scholar 

  66. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW (2004) Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 24:63–70

    Article  CAS  PubMed  Google Scholar 

  67. Richy F, Ethgen O, Bruyere O, Reginster J-Y (2004) Efficacy of alfacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int (published online)

  68. Sambrook P, Henderson NK, Keogh A, Macdonald P, Glanville A, Spratt P (2000) Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Min Res 15:1818–1824

    CAS  Google Scholar 

  69. Akesson K, Lau KHW, Baylink DJ (1997) Rationale for active vitamin D analog therapy in senile osteoporosis. Calcif Tissue Int 60:100–105

    Article  CAS  PubMed  Google Scholar 

  70. Tanizawa T, Imura K, Ishii Y, Nishida S, Takano Y, Mashiba T, Endo N, Takahashi HE (1999) Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study. Osteoporos Int 9:163–170

    Article  CAS  PubMed  Google Scholar 

  71. Fujita T, Fukase M, Shimada T, Yamamoto H (1992) Treatment of established osteoporosis with 1α-(OH)-vitamin D3 and low dose intermittent Elcalcitonin (eel calcitonin derivative). JBBM 10:37–40

    Google Scholar 

  72. Ushiroyama T, Ikeda A, Sakai M, Higashiyama T, Ueki M (2001) Effects of combined use of calcitonin and 1α-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low-dose calcitonin. Maturitas 40:229–238

    Article  CAS  PubMed  Google Scholar 

  73. Frediani B, Allegri A, Bisohno S, Marcolongo R (1998) Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis. Two years of continuous treatment. Clin Drug Invest 14:235–244

    Google Scholar 

  74. Gallagher JC, Fowler SE, Detter JR, Sherman SS (2001) Combination treatment with estrogen and calcitriol in prevention of age-related bone loss. J Clin Endocrinol Metab 86:3618–3628

    Article  CAS  PubMed  Google Scholar 

  75. Ringe JD (2001) Osteoporosis in dialogue: 100 questions—100 answers. Thieme, Stuttgart, pp 79–80

    Google Scholar 

  76. Paschalis EP, Burr DB, Mendelsohn R, Hock JM, Boskey AL (2003) Bone mineral and collagen quality in humeri of ovariectomized Cynomolgus monkeys given rhPTH(1–34) for 18 months. J Bone Miner Res 18:769–775

    CAS  PubMed  Google Scholar 

  77. Shibata T, Shira-Ishi A, Sato T, Masaki T, Sasaki, A, Masuda Y, Hishiya A, Ishikura N, Higashi S, Uchida Y, Saito M, Ito M, Ogata E, Watanabe K, Ikeda K (2002) Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 17:622–629

    CAS  PubMed  Google Scholar 

  78. Endo I, Inoue D, Mitsui T, Umaki Y, Akaike M, Yoshizawa T, Kato S, Matsumoto T (2003) Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 144:5138–5144

    Article  CAS  PubMed  Google Scholar 

  79. Koike T, Okawa T, Wada M, Kita T, Takaoka K (2003) Effects of a long-term alfacalcidol or calcitonin administration on body sway in Japanese elderly women. J Bone Min Res 18 [Suppl 2]:168

    Google Scholar 

  80. Gallagher JC, Haynafzki G, Fowler S (2003) Calcitriol therapy reduces falls and fractures in elderly women. Calcif Tissue Int 72:334

    Google Scholar 

  81. Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN, Thalmann B, Stähelin HB (2004) Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. JAGS 52:230–236

    Google Scholar 

  82. Henderson-Briffa K, Keogh A, Sambrook PN, Eismann JA (2003) Reduction by calcitriol of immunosuppressive therapy requirements in heart transplantation. Transplantation 75:2133–2134

    PubMed  Google Scholar 

  83. Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D (2004) Alendronate or calcitriol and prevention of bone loss after cardiac transplantation. N Engl J Med 350 (in press)

  84. Van Staa, TP, Leufkens HGM, Abenhaim A, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000

    PubMed  Google Scholar 

  85. Sato Y, Manabe S, Kuno H, Oizumi K (1999) Amelioration of osteopenia and hypovitaminosis D by 1α-hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 66:64–68

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatologie/Osteologie, Medizinisches Klinik 4, Klinikum Leverkusen, Akademisches Lehrkrankenhaus der Universität zu Köln, 51375, Leverkusen, Germany

    Johann D. Ringe & Erich Schacht

Authors
  1. Johann D. Ringe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erich Schacht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johann D. Ringe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ringe, J.D., Schacht, E. Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int 24, 189–197 (2004). https://doi.org/10.1007/s00296-004-0454-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-004-0454-0

Keywords

Search

Navigation